<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEMANTINE</span><br/>(me-man'teen)<br/><span class="topboxtradename">Namenda<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">n-methyl-d-aspartate (nmda) receptor antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets; 2 mg/mL solution</p>
<h1><a name="action">Actions</a></h1>
<p>Glutamate activation at the (<i>N</i>-methyl-<small>D</small>-aspartate) NMDA receptor is needed for memory and learning processes in the brain. Excess glutamate may play a role in Alzheimer's
         disease by over-stimulating NMDA receptors, thus causing increased Ca<sup>2+</sup> movement into neurons leading to neuronal damage. Memantine is a low-affinity, uncompetitive antagonist at NMDA receptors
         in the brain. Blockade of NMDA receptors by memantine may slow intracellular calcium accumulation, and help to prevent further
         nerve damage without interfering with the physiological actions of glutamate that are required for memory and learning.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improves cognitive functioning in moderate-to-severe Alzheimer's disease (AD) and in mild-to-moderate vascular dementia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of symptoms of moderate to severe Alzheimer's disease</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of moderate to severe vascular dementia</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety and efficacy in children are unknown.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe renal impairment; concurrent use with carbonic anhydrase inhibitors, or sodium bicarbonate, pregnancy (category
         B), lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Alzheimer's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 5 mg once daily, increase dose by 5 mg/wk over a 3-wk period to target dose of 10 mg b.i.d.<br/><br/><span class="impairmenttitle">Severe Renal Impairment</span><br/>Decrease to 5 mg b.i.d.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: The recommended interval between dose increases is 1 wk.
            			
         </li>
<li>Dose reductions should be considered with moderate renal impairment.</li>
<li>Store between 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, pain, flu-like symptoms, peripheral edema. <span class="typehead">CNS:</span> Dizziness, headache, confusion, somnolence, hallucinations, agitation, insomnia, abnormal gait, depression, anxiety, syncope,
      TIA, vertigo, ataxia, hypokinesia, aggressive reaction. <span class="typehead">CV:</span> Hypertension, cardiac failure. <span class="typehead">GI:</span> Constipation, vomiting, diarrhea, nausea, anorexia. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">Metabolic:</span> Weight loss, increased alkaline phosphatase. <span class="typehead">Musculoskeletal:</span> Back pain, arthralgia. <span class="typehead">Respiratory:</span> Coughing, dyspnea, bronchitis, upper respiratory infections, pneumonia. <span class="typehead">Skin:</span> Rash. <span class="typehead">Special Senses:</span> Conjunctivitis. <span class="typehead">Urogenital:</span> Urinary incontinence, UTI, frequent micturition. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Drugs that increase the pH of the urine (<small>CARBONIC ANHYDRASE INIBITORS</small>, <b>sodium bicarbonate</b>) may increase levels of memantine; may enhance the effects of <b>amantadine,</b>
<b>dextromethorphan,</b>
<b>ketamine,</b>
<b>bromocriptine,</b>
<b>pergolide,</b>
<b>pramipexole,</b> and <b>ropinirole;</b> may enhance the adverse effects of <b>levodopa</b>-containing drugs. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 100% absorbed from GI tract. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Distribution:</span> Easily crosses the blood-brain barrier. <span class="typehead">Metabolism:</span> Minimal metabolism. <span class="typehead">Elmination:</span> Primarily excreted unchanged in urine. Increases in urinary pH can decrease elimination of drug. <span class="typehead">Half-Life:</span> 6080 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor respiratory and CV status, especially with preexisting heart disease.</li>
<li>Assess for and report S&amp;S of focal neurologic deficits (e.g., TIA, ataxia, vertigo).</li>
<li>Lab tests: Periodic Hct &amp; Hgb, serum sodium, alkaline phosphatase, and blood glucose.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to the physician: problems with vision, skin rash, shortness of breath, swelling in throat or
            tongue, agitation or restlessness, confusion, dizziness, or incontinence.
         </li>
<li>Do not drive or engage in other hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>